Literature DB >> 17582056

Dolasetron overdose resulting in prolonged QTc interval and severe hypotension: a case report and literature review.

Martin Rochford1, Thomas J Kiernan, Amjed Aziz.   

Abstract

Dolasetron (Anzemet) overdose is uncommon, and, to our knowledge, this is the only case report of an intentional overdose. Dolasetron (dolasetron mesylate) is a selective 5-hydroxytryptamine 3 antagonist derived from pseudopelletierine, and is used in the prevention and treatment of nausea and vomiting. Transient and asymptomatic ECG changes, including QRS widening and PR and QTc prolongation, have been reported in therapeutic doses. The case of a 21-year-old woman who presented after an intentional overdose of 10x200 mg dolasetron tablets resulting in prolongation of the QTc interval and severe hypotension is reported here. Management of hypotension included intravenous fluid resuscitation and norepinephrine infusion with invasive monitoring in a high dependency unit. Sodium cardiac channel block contributes to cardiotoxicity observed in dolasetron overdose. Sodium bicarbonate was used in an attempt to reduce cardiac sodium channel block, although we observed no apparent benefit. As dolasetron becomes more commonly used in the outpatient setting, both doctors and patients need to be aware of the dangers of dolasetron in toxic doses. The pharmacology and toxicology of dolasetron are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582056      PMCID: PMC2658414          DOI: 10.1136/emj.2006.042002

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  2 in total

1.  Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation.

Authors:  J L McCabe; D J Cobaugh; J J Menegazzi; J Fata
Journal:  Ann Emerg Med       Date:  1998-09       Impact factor: 5.721

2.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.

Authors:  Y A Kuryshev; A M Brown; L Wang; C R Benedict; D Rampe
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

  2 in total
  3 in total

1.  Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.

Authors:  S Michael Roberts; Dmitri S Bezinover; Piotr K Janicki
Journal:  Cancer Manag Res       Date:  2012-02-24       Impact factor: 3.989

2.  Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates.

Authors:  Sebastian Polak; Michael K Pugsley; Norman Stockbridge; Christine Garnett; Barbara Wiśniowska
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

3.  Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.

Authors:  Joel Morganroth; Kristen K Flaharty; Simona Parisi; Cecilia Moresino
Journal:  Support Care Cancer       Date:  2015-06-26       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.